Articles On Cynata Therapeutics (ASX:CYP)

ASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics has enrolled the first patient suffering from respiratory failure for a clinical trial that it has called “MEND” testing its proprietary Cymerus mesenc...

Summary Frontier Resources has successfully completed its landowner MRA Warden’s hearing as part of the renewal process of its wholly owned tenement. Vection Technologies has achieved a milestone of completing its first public hospital...

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

ASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics is looking for patients who are suffering from osteoarthritis in the knees and severe respiratory distress for two separate clinical trials currently u...

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The health...

Cynata Therapeutics has received ethics committee approval to expand the recruitment criteria of its active “MEND” clinical trial in patients in intensive care with respiratory failure. The trial will now look beyond just patients suffering...

Source:Cryptographer, Shutterstock Summary Stem cell and regenerative medicine player Cynata Therapeutics will expand recruitment criteria for its active MEseNchymal coviD-19 clinical trial. Oventus medical enters into a virtual Lab i...

Stem cell therapeutics company Cynata's (ASX: CYP) pool of eligible patients in a COVID-19 treatment trial will be increased after the company received ethics committee approval to include those suffering from respiratory failure. The exp...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

2021 is set to be another big year for ASX capital raisings with solid volumes so far in 2021. In the first nine weeks of the new year, ASX companies have raised over $1.96 billion. Although this is lower than the $3 billion raised in the f...

Source: Guschenkova, Shutterstock Summary Medical technology player Nova Eye Medical announced the publication of positive patient follow-up data from a sub-study analysis of the LEAD trial. Cynata Therapeutics has initiated a new stu...

Having already successfully demonstrated the efficacy and safety of its proprietary stem cells on rodents with lung disease, Cynata Therapeutics is now set to embark on a new study on mice designed to find out how and why its stem cells wor...

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has announced the initiation of a new study to investigate its Cymerus mesenchymal stem cells. 

Cynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology in the hope of commercialising TekCyte’s proprietary surface modifications of polymer-coated dressings for the delivery of Cynata’s mesenchym...

COVID-19 vaccines have reached Australia but ASX stocks that were making anti-COVID 19 drugs or tests are pushing on. The outbreak of the pandemic caused a number of ASX companies (big and small) to pivot to fighting COVID-19. In the last f...

Cynata Therapeutics’ recent run of successful capital raisings has been bolstered by a lazy $1.39m tax refund courtesy of the Federal Government’s Research & Development Tax Incentive grant scheme, adding to its already burgeoning $24.9...

Cynata Therapeutics (ASX: CYP), founded by two clever stem cell researchers and one wise Australian techpreneur, is in the process of developing a treatment for COVID-19. Using its in-house stem cell technology Cymerus, the ASX-listed bio...

Cynata Therapeutics (ASX: CYP), founded by two clever stem cell researchers and one wise Australian techpreneur, is in the process of developing a treatment for COVID-19. Using its in-house stem cell technology Cymerus, the ASX-listed bio...

If 2020 taught us anything, it was the importance of quality healthcare. The COVID-19 pandemic put unprecedented demand on global health services, with many providers rising to the challenge. Healthcare has long been seen as a defensive in...

Summary Healthcare firms across the world are working like a Trojan to seek an effective treatment for COVID-19. Some ASX-listed healthcare stocks contributing in COVID-19 battle seem to hold the robust potential to do wonders over the...

ASX large cap biotech Mesoblast (ASX:MSB) is not alone in fighting Acute Respiratory Distress Syndrome (ARDS). ARDS is a disease that hinders the lungs’ ability to operate and is a major culprit of COVID-19 deaths. Essentially it causes lun...

Melbourne-based biotechnology company, Cynata Therapeutics, has commenced a Phase 3 clinical trial using its Cymerus stem cell product “CYP-004” to treat patients suffering from osteoarthritis. Osteoarthritis is just one of many ailments th...

Melbourne-based biotechnology company, Cynata Therapeutics, has commenced a Phase 3 clinical trial using its Cymerus stem cell product “CYP-004” to treat patients suffering from osteoarthritis. Osteoarthritis is just one of many ailments th...

Presenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:PXS).

Ongoing studies of Cynata Therapeutics’ Cymerus stem cell products are beginning to reveal a wide range of commercial possibilities for the ASX-listed company’s cutting edge biotechnology that it is looking to apply to a multitude of ailmen...

ASX-listed Cynata Therapeutics, a Melbourne-based, clinical-stage biotech company specialising in cell therapeutics, has produced trial results confirming the initial success of its Cymerus mesenchymal stem cells, or “MSCs” ability to resto...

ShareCafeCynata Therapeutics – ShareCafe Hidden Gems Webinar Presentation   Presenter – Dr. Ross Macdonald – CEO & MD – Cynata is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of th...

ShareCafeHidden Gems Webinar Recap – OSL, MDC, CYP, GSS   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from Oncosil Medical (ASX:OSL), Medlab Clinical...

Canary Capital is making a huge bet on a company that thinks stem cells aren’t the future of medicine. The small- and micro-cap Sydney investment house has just finished a $10m capital raising for regenerative medicine company Exopharm, a M...

Australian company Cynata Therapeutics (ASX:CYP) says it has begun patient enrolment in its MEND (MEseNchymal coviD-19) trial.

The Cynata Therapeutics Ltd (ASX: CYP) share price leapt by as much as 14% this morning as patient enrolment begins on the company’s COVID-19 trial. Cynata is trialling the use of its Cymerus MSC technology in COVID-19 patients with respi...

While treatments for pain management per se may not receive as much attention as those related to cures for chronic diseases, every day there is a large universe of people who attempt to treat but mismanage agonising and debilitating condit...

By Tim Boreham, Editor, The New Criterion The ASX biotechs surfing the COVID-19 story Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the d...

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Ross Macdonald, CEO of Cynata Thera...

Fortunes were to be made in ASX health stocks during March and April as investors looked for salvation from the COVID-19 pandemic fears rocking markets. However, once the two biggest health stocks Resmed (ASX:RMD) and CSL (ASX:CSL) are take...

In the last fortnight another two dozen directors of ASX small caps made trades above $100,000 and a number of them chipped into potash stocks. COVID-19 was the last thing potash stocks needed having been struggling prior to the pandemic. T...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

COVID-19 vaccines are driving markets but treatments are where most people believe a solution to the pandemic lies. However, use of the two most famous treatments to date — Gilead Sciences’ HIV drug remdesivir and US President Donald Trump’...

Biotechnology company Cynata Therapeutics (ASX: CYP) intends to develop a treatment for COVID-19 by repurposing its Cymerus mesenchymal stem cells (MSCs) products and research. In a statement to the market, Cynata said it had received ethic...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Our summary of Cynata Therapeutics Ltd's recent announcement What's happened? Cynata Therapeutics Ltd (ASX:CYP "Cynata") has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s propriet...

The COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand the last two months, up 36 per cent on the prior two months as many organisations deem the patient risk of exposure to be too high. Globally,...

Clinical-stage biotechnology company specialising in cell therapeutics Cynata Therapeutics (ASX:CYP) has provided an update on the planned clinical trials of its Cymerus mesenchymal stem cell products for osteoarthritis and critical...

The S&P/ASX 200 index (ASX: XJO) has followed the lead of U.S. markets and is trading notably lower again on Friday. At the time of writing the benchmark index is down 6.7% to 4,947 points. Four shares that have managed to avoid the se...